MEK inhibitors for heart thickening in RASopathies
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Heart & circulation, Skin clinical trials.
This trial tests a targeted drug (MEK inhibitor) to treat thickened heart muscle caused by a group of genetic conditions called RASopathies. It may help improve heart function in people with hypertrophic cardiomyopathy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of a RASopathy (a genetic condition).
- You have a diagnosis of hypertrophic cardiomyopathy (thickened heart muscle).
- Your caregivers (if you are a child) have signed a consent form agreeing to participate.
- You do not have allergies or medical conditions that prevent you from taking propranolol, disopyramide, or trametinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores health samples and information from people with RASopathy conditions (like Noonan or Costello syndromes) and from family members who may not have the condition. It helps researchers understand these disorders and supports future studies that could lead to better care.
This study looks at people who have a RASopathy—a genetic condition—and also have solid tumors (tumor growths not in blood). To join, your RASopathy must be confirmed by genetic testing, not only by symptoms.
This study looks at medical records of children with a genetic condition called RASopathy who developed thickened heart muscle and needed hospital care for heart failure in their first six months of life. The goal is to understand how the heart condition progresses over time.
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
Hear when a new Noonan Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.